Oruka Therapeutics, Inc.
Financials
Valuation Metrics
Oruka Therapeutics, Inc.'s Market Cap is $6.29B. At end of 2025 it was $1.65B. Ranked #1167 of 3,121 in US market (top 37%), #387 of 1,463 on NASDAQ (top 26%), #64 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 24%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $6.29B | US#1,167/3,121 Sec#64/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-133M | US—/3,121 Sec—/266 |
| Total Assets | $1.14B | US#2,417/3,121 Sec#92/266 |
| Net Assets | $1.11B | US#1,697/3,121 Sec#59/266 |
| Employees | 68 | US#2,681/3,121 Sec#198/266 |
| Value | ||
| P/B | 5.64x | US#2,330/3,121 Sec#154/266 |
| FCF Yield | -1.61% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -11.92% | US#2,394/3,121 Sec#84/266 |
| ROA | -11.66% | US#2,694/3,121 Sec#106/266 |
| Financial Health | ||
| Debt Ratio | 2.23% | US#23/3,121 Sec#5/266 |
| Total Debt | $3M | US#2,955/3,121 Sec#233/266 |
| FCF | $-101M | US#2,628/3,121 Sec#143/266 |
| Cash | $268M | US#1,502/3,121 Sec#89/266 |
| Current Ratio | 38.51x | US#66/3,121 Sec#6/266 |
| Performance | ||
| 1Y Return | 472.74% | US#11/3,121 Sec#8/266 |
| 1M Return | -13.43% | US#2,725/3,121 Sec#209/266 |
| From 52W High | -17.80% | US#1,160/3,121 Sec#79/266 |
| 1Y MDD | -27.99% | US#1,278/3,121 Sec#80/266 |
| Trading | ||
| Volume | 1,699,534 shares | US#1,379/3,121 Sec#150/266 |
| Trading Value | $163M | US#833/3,121 Sec#53/266 |
| Per Share | ||
| EPS | $-2.01 | US—/3,121 Sec—/266 |
| BPS | $16.83 | US#1,424/3,121 Sec#45/266 |
Company Info
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.